iLite® VEGF Assay Ready Cells is a human embryonic kidney cell line (HEK-293*; ATCC #CRL-1573) that have been genetically engineered and optimized to respond to VEGF with specific, proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a NanoLuc Luciferase reporter gene construct, under control of a constitutive promotor.
* The HEK-293 cell line has been used under a license obtained from AdVec Inc.
The iLite® VEGF Assay Ready Cells can be used for the quantification of VEGF activity, VEGF inhibitor activity and for determination of neutralizing antibodies against VEGF inhibitors in human serum.
Application notes for the following assays are available:
• Quantification of functional VEGF using iLite® VEGF Assay Ready Cells (E-216-GB)
• Quantification of VEGF inhibitor activity using iLite® VEGF Assay Ready Cells (E-203-GB)
• Determination of neutralizing antibodies against VEGF inhibitors using iLite® VEGF Assay Ready Cells (E-204-GB)
Vascular Endothelial Growth Factor (VEGF) is a signalling protein which is involved in both normal vascular growth and pathological angiogenesis. Without angiogenesis, growth of solid tumours would be limited by oxygen supply. Tumours which express VEGF can overcome this limitation and are thus able to grow and metastasize. For this reason, different anti-cancer therapies targeting VEGF have emerged, e.g. a humanized anti-VEGF antibody such as bevacizumab (AvastinTM, Genentech) is currently widely used as a first-line therapy for colorectal cancer (1,2).
>250µl of Assay Ready Cells suspended in DMEM medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).